Why Incyte Stock Lost 11% in April
Investors braced for bad earnings news from the biotech specialist, but Incyte surpassed those expectations late in the month.
Incyte
INCY
INCY
$81.96
$1.46
0.0%
BATS BZX Real Time Price as of May 24, 2019, 3:38 p.m.
View Interactive INCY Charts
The Company is a drug discovery and development company focused on developing proprietary small molecule drugs to treat serious unmet medical needs.
News & Analysis: Incyte
The Fool has written over 200 articles on Incyte.
All
Market Moves
Podcasts
Earnings
Incyte Corp (INCY) Q1 2019 Earnings Call Transcript
INCY earnings call for the period ending March 31, 2019.
2 Hot Stocks to Buy in March
A fast-growing pharma and a leader in solar-power hardware have soared in 2019, but they're still buys for investors with a long-term mind-set.
Incyte (INCY) Q4 2018 Earnings Conference Call Transcript
INCY earnings call for the period ending December 31, 2018.
Why Incyte Stock Gained 27% in January
The biotech attracted more optimism from Wall Street ahead of its upcoming fourth-quarter report.
Why Celgene, Agenus, and Incyte Jumped Today
Biotech was a popular sector today. Find out why.
Here Are Biotech’s Big Pipeline Disappointments in 2018
A number of companies suffered setbacks this year.
Immuno-Oncology Suffered a Setback in 2018. What’s Next?
Checkpoint inhibitors remain top sellers, but it wasn’t all rosy news this year.
Incyte's Shares Have Taken a Beating in 2018 -- Here's Why
Here's what we can learn from the failure of Incyte's highly-touted cancer therapy.
Incyte Corp (INCY) Q3 2018 Earnings Conference Call Transcript
INCY earnings call for the period ending September 30, 2018.
